Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck announces significant advancements in gender diversity within its small molecule process research & development (SM PR&D) team, with the representation of women nearly doubling over the past seven years. Jamie McCabe Dunn, Director of Process Chemistry, emphasizes that diversity and inclusion drive innovation. Initiatives include active recruitment by women leaders and partnerships with academic institutions. Recognizing the contributions of female scientists, 12 women from the department have received prestigious awards in the last three years. The company asserts its commitment to fostering a more equitable environment for future generations.
Merck (NYSE: MRK) announced that its Phase 3 NRG-GY018 trial of KEYTRUDA, in combination with chemotherapy, significantly improved progression-free survival (PFS) in patients with stage III-IV or recurrent endometrial carcinoma. This trial met its primary endpoint, showing meaningful results for both mismatch repair proficient (pMMR) and deficient (dMMR) patients. The safety profile was consistent with previous studies, with no new safety signals. These findings will be presented at an upcoming medical meeting. KEYTRUDA's promising results highlight its potential as a treatment option for advanced endometrial cancer, which often has limited options.
Merck (NYSE: MRK) reported an exceptional financial performance for 2022, with a 22% increase in worldwide sales to $59.3 billion and a 17% rise in GAAP EPS to $5.71. Fourth-quarter sales reached $13.8 billion, marking a 2% year-on-year increase and 8% excluding foreign exchange impacts. KEYTRUDA, Merck's leading oncology drug, saw sales grow by 22% to $20.9 billion. The company's 2023 outlook anticipates sales between $57.2 billion and $58.7 billion and GAAP EPS between $5.86 and $6.01, incorporating an expected $1.0 billion in LAGEVRIO sales.
Merck (NYSE: MRK) announced FDA approval for KEYTRUDA as a single agent for adjuvant treatment in adults with stage IB, II, or IIIA non-small cell lung cancer (NSCLC) after surgical resection and platinum-based chemotherapy. This marks the fifth indication for KEYTRUDA in NSCLC and the 34th overall in the U.S. The approval stems from the KEYNOTE-091 trial, which showed a 27% reduction in disease recurrence or death compared to placebo, with a median disease-free survival of 58.7 months for the KEYTRUDA group versus 34.9 months for placebo. The treatment offers a new option for patients with stage IB disease, regardless of PD-L1 expression.
Merck Animal Health, a division of Merck & Co., Inc. (NYSE:MRK), has received FDA approval for the expanded use of BRAVECTO® Chews for Dogs, now treating and controlling infestations of the Asian longhorned tick. This is the first product in the U.S. addressing this invasive tick species, which poses health risks to pets and humans. The approval enhances BRAVECTO's comprehensive parasite protection portfolio, underscoring Merck's commitment to innovative veterinary solutions. With over 250 million doses distributed since 2014, BRAVECTO aims to offer pets prolonged protection against various parasites.
Merck (NYSE: MRK) has announced the cessation of the Phase 3 KEYNOTE-991 trial for KEYTRUDA, its anti-PD-1 therapy, in combination with enzalutamide and androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). This decision follows a recommendation from an independent Data Monitoring Committee after an interim analysis revealed no improvement in overall survival or radiographic progression-free survival compared to the control group. Although no new safety signals were identified, the combination treatment exhibited a higher rate of Grade 3-5 adverse events. Merck remains committed to developing new treatment options for prostate cancer.
Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-966 trial, demonstrating that KEYTRUDA, in combination with chemotherapy, significantly improves overall survival for patients with advanced biliary tract cancer compared to chemotherapy alone. The safety profile was consistent with earlier studies. With biliary tract cancer's poor prognosis, highlighted by only 5% to 15% five-year survival rates, these results offer hope for new treatment options. Merck plans to present results at a medical meeting and submit them to regulatory authorities while continuing to explore KEYTRUDA's use in various gastrointestinal cancers.
Merck (NYSE: MRK) has declared a quarterly dividend of $0.73 per share for Q2 2023. Shareholders of record will receive this payment on April 10, 2023, with the record date being March 15, 2023. Merck aims to leverage leading-edge science to improve lives worldwide, boasting over 130 years in the biopharmaceutical industry. The company emphasizes research and innovation in health solutions for both people and animals, while fostering a diverse and inclusive workforce.
Perceiv AI has been chosen for the inaugural cohort of the Merck Digital Sciences Studio (MDSS), receiving funding and mentorship from Merck (NYSE: MRK), Northpond Ventures, and McKesson Ventures. This selection, announced on January 17, 2023, is a significant milestone for Perceiv AI, highlighting their innovative prognostic platform that integrates multimodal data to address neurodegenerative diseases. The MDSS program aims to enhance drug discovery and development through collaborations and access to advanced technology. Perceiv AI plans to expand its ForesightTM platform to develop biomarkers for conditions like Alzheimer's disease.
Summary not available.